ArticleJournal for immunotherapy of cancer2026
Limited expression of B-cell maturation antigen in acute myeloid leukemia.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell maturation antigen (BCMA) was recently identified as a target of T-cell-directed therapy for acute myeloid leukemia (AML), based on the study reporting high BCMA abundance in AML cells using the flow cytometry anti-BCMA antibody clone 19F2 (BCMA-19F2). However, our independent investigation demonstrated limited BCMA levels in both AML patient samples and AML cell lines through the analysis of established transcriptome profiles. The low BCMA expression in AML cells was validated by flow cytometry using an alternative anti-BCMA antibody (clone REA315) and western blotting. Importantly, we unveiled that the BCMA-19F2 could bind non-specifically to AML cells via its non-antigen-binding fragment, as evidenced by the isotype control experiment and Fc receptor blocking assay. Furthermore, cytotoxicity assay confirmed that the leukemic cell lysis was minimal on the treatment of anti-BCMA CAR T cells. Our data suggest that BCMA expression is restricted in AML, and the BCMA-19F2 is unsuitable for BCMA detection in the context of AML samples. It underscores that the accurate assessment of tumor antigen is paramount for therapeutic target design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.